Search

Medical images play an important role in medical diagnosis and treatment. Oncologists analyze images to determine the different characteristics of deadly diseases, plan the therapy, and observe the evolution of the disease. The objective of this paper is to propose a method for the detection of brain tumors. Brain tumors are identified from Magnetic Resonance (MR) images by performing suitable segmentation procedures. The latest technical literature concerning radiographic images of the brain shows that deep learning methods can be implemented to extract specific features of brain tumors, aiding clinical diagnosis. For this reason, most data scientists and AI researchers work on Machine Learning methods for designing automatic screening procedures. Indeed, an automated method would result in quicker segmentation findings, providing a robust output with respect to possible differences in data sources, mostly due to different procedures in data recording and storing, resulting in a more consistent identification of brain tumors. To improve the performance of the segmentation procedure, new architectures are proposed and tested in this paper. We propose deep neural networks for the detection of brain tumors, trained on the MRI scans of patients' brains. The proposed architectures are based on convolutional neural networks and inception modules for brain tumor segmentation. A comparison of these proposed architectures with the baseline reference ones shows very interesting results. MI-Unet showed a performance increase in comparison to baseline Unet architecture by 7.5 % in dice score, 23.91 % insensitivity, and 7.09 % in specificity. Depth-wise separable MI-Unet showed a performance increase by 10.83 % in dice score, 2.97 % in sensitivity, and 12.72 % in specificity as compared to the baseline Unet architecture. Hybrid Unet architecture achieved performance improvement of 9.71 % in dice score, 3.56 % in sensitivity, and 12.6 % in specificity. Whereas the depth-wise separable hybrid Unet architecture outperformed the baseline architecture by 15.45 % in dice score, 20.56 % in sensitivity, and 12.22 % in specificity. [ABSTRACT FROM AUTHOR]

Glioblastoma (GB) and brain metastasis (BM) are the most frequent types of brain tumors in adults. Their therapeutic management is quite different and a quick and reliable initial characterization has a significant impact on clinical outcomes. However, the differentiation of GB and BM remains a major challenge in today's clinical neurooncology due to their very similar appearance in conventional magnetic resonance imaging (MRI). Novel metabolic neuroimaging has proven useful for improving diagnostic performance but requires artificial intelligence for implementation in clinical routines. Here; we investigated whether the combination of radiomic features from MR-based oxygen metabolism ("oxygen metabolic radiomics") and deep convolutional neural networks (CNNs) can support reliably pre-therapeutic differentiation of GB and BM in a clinical setting. A self-developed one-dimensional CNN combined with radiomic features from the cerebral metabolic rate of oxygen (CMRO2) was clearly superior to human reading in all parameters for classification performance. The radiomic features for tissue oxygen saturation (mitoPO2; i.e., tissue hypoxia) also showed better diagnostic performance compared to the radiologists. Interestingly, both the mean and median values for quantitative CMRO2 and mitoPO2 values did not differ significantly between GB and BM. This demonstrates that the combination of radiomic features and DL algorithms is more efficient for class differentiation than the comparison of mean or median values. Oxygen metabolic radiomics and deep neural networks provide insights into brain tumor phenotype that may have important diagnostic implications and helpful in clinical routine diagnosis. [ABSTRACT FROM AUTHOR]

Simple Summary: With the advancement of artificial intelligence, including machine learning, the field of oncology has seen promising results in cancer detection and classification, epigenetics, drug discovery, and prognostication. In this review, we describe what artificial intelligence is and its function, as well as comprehensively summarize its evolution and role in breast, colorectal, and central nervous system cancers. Understanding the origin and current accomplishments might be essential to improve the quality, accuracy, generalizability, cost-effectiveness, and reliability of artificial intelligence models that can be used in worldwide clinical practice. Students and researchers in the medical field will benefit from a deeper understanding of how to use integrative AI in oncology for innovation and research. Well-trained machine learning (ML) and artificial intelligence (AI) systems can provide clinicians with therapeutic assistance, potentially increasing efficiency and improving efficacy. ML has demonstrated high accuracy in oncology-related diagnostic imaging, including screening mammography interpretation, colon polyp detection, glioma classification, and grading. By utilizing ML techniques, the manual steps of detecting and segmenting lesions are greatly reduced. ML-based tumor imaging analysis is independent of the experience level of evaluating physicians, and the results are expected to be more standardized and accurate. One of the biggest challenges is its generalizability worldwide. The current detection and screening methods for colon polyps and breast cancer have a vast amount of data, so they are ideal areas for studying the global standardization of artificial intelligence. Central nervous system cancers are rare and have poor prognoses based on current management standards. ML offers the prospect of unraveling undiscovered features from routinely acquired neuroimaging for improving treatment planning, prognostication, monitoring, and response assessment of CNS tumors such as gliomas. By studying AI in such rare cancer types, standard management methods may be improved by augmenting personalized/precision medicine. This review aims to provide clinicians and medical researchers with a basic understanding of how ML works and its role in oncology, especially in breast cancer, colorectal cancer, and primary and metastatic brain cancer. Understanding AI basics, current achievements, and future challenges are crucial in advancing the use of AI in oncology. [ABSTRACT FROM AUTHOR]